Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus anlotinib for advanced solid tumors
ChiCTR2100051610Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin and anlotinib in Nonhematologic neoplasms, sponsored by Shanghai Sixth People's Hospital. Primary endpoints: tumor size, objective response rate and 4 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
eribulinanlotinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100051610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051610.